Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 303, Issue 7, 2012, Pages

  Cherney, David Z I ^a   Reich, Heather N ^a   Jiang, Shan ^a   Har, Ronnie ^a   Nasrallah, Rania ^b   Hébert, Richard L ^b   Lai, Vesta ^a   Scholey, James W ^a   Sochett, Etienne B ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Endothelial function; Hyperfiltration; Nitric oxide; Type 1 diabetes

Indexed keywords

CYCLIC GMP; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MALE; PRIORITY JOURNAL; VASODILATATION;

ADULT; BRACHIAL ARTERY; CYCLIC AMP; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; RENAL CIRCULATION; VASODILATION;

EID: 84867242387     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00286.2012     Document Type: Article

References (62)

1. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol Renal Fluid Electrolyte Physiol 268: F885-F898, 1995.
2. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol Renal Fluid Electrolyte Physiol 270: F845-F851, 1996.
3. Bell TD, DiBona GF, Biemiller R, Brands MW. Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked. humans. Am J Physiol Renal Physiol 295: F1449-F1456, 2008.
4. Blantz RC, Deng A, Lortie M, Munger K, Vallon V, Gabbai FB, Thomson SC. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int 61: 782-785, 2002.
5. Boone M, Kortenoeven M, Robben JH, Deen PM. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus. Nephrol Dial Transplant 25: 48-54, 2010.
6. Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoformspecific protein kinase C beta inhibitor, ruboxistaurin. J Diabetes Complications 22: 88-95, 2008.
7. Cherney DZ, Lai V, Miller JA, Scholey JW, Reich HN. The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans. Nephrol Dial Transplant 25: 4093-4096, 2010.
8. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hebert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688-695, 2008.
9. Cherney DZ, Miller JA, Scholey JW, Nasrallah R, Hebert RL, Dekker MG, Slorach C, Sochett EB, Bradley TJ. Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care 33: 1344-1346, 2010.
10. Cherney DZ, Sochett EB, Lai V, Dekker MG, Slorach C, Scholey JW, Bradley TJ. Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes. Diabetes Care 33: 2068-2070, 2010.
11. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 32: 13767-13770, 1993.
12. Craven PA, Caines MA, DeRubertis FR. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 36: 95-103, 1987.
13. Dalla Vestra M, Sacerdoti D, Bombonato G, Fioretto P, Finucci G, Saller A, Sfriso A, Bruseghin M, Sambataro M, Velussi M, Baggio B, Nosadini R, Crepaldi G. Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. Eur J Endocrinol 146: 687-694, 2002.
14. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62: 351-356, 1963.
15. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest 89: 1248-1256, 1992.
16. De Vriese AS, Van de Voorde J, Blom HJ, Vanhoutte PM, Verbeke M, Lameire NH. The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia 43: 1116-1125, 2000.
17. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 15: 3-9, 2002.
18. DeRubertis FR, Craven PA. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 22: 727-735, 1993.
19. Dijkhorst-Oei LT, Boer P, Rabelink TJ, Koomans HA. Nitric oxide synthesis inhibition does not impair water immersion-induced renal vasodilation in humans. J Am Soc Nephrol 11: 1293-1302, 2000.
20. Esmatjes E, Conget JI, Gaya J, Fernandez MR, Ferrer JP, Rivera F, Vilardell E. Effects of thromboxane synthesis inhibitor triflusal on renal hemodynamics in microalbuminuric diabetic patients. Diabetes Care 13: 1114-1117, 1990.
21. Ficociello LH, Perkins BA, Silva KH, Finkelstein DM, Ignatowska-Switalska H, Gaciong Z, Cupples LA, Aschengrau A, Warram JH, Krolewski AS. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2: 461-469, 2007.
22. Florijn KW, Barendregt JN, Lentjes EG, van Dam W, Prodjosudjadi W, van Saase JL, van Es LA, Chang PC. Glomerular filtration rate easurement by "single-shot" injection of inulin. Kidney Int 46: 252-259, 1994.
23. Gonzalez E, Rosello-Catafau J, Jawerbaum A, Vela J, Sinner D, Pustovrh C, White V, Xaus C, Peralta C, Gimeno MA. Involvement of inducible isoforms of COX and NOS in streptozotocin-pancreatic damage in the rat: interactions between nitridergic and prostanoid pathway. Prostaglandins Leukot Essent Fatty Acids 64: 311-316, 2001.
24. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y. Modulation of endotheliumdependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92: 3431-3435, 1995.
25. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Kamp O, Bouter LM, Stehouwer CD. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not. The Hoorn Study. Atherosclerosis 174: 49-56, 2004.
26. Hiragushi K, Sugimoto H, Shikata K, Yamashita T, Miyatake N, Shikata Y, Wada J, Kumagai I, Fukushima M, Makino H. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normoand micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract 53: 149-159, 2001.
27. Ito A, Uriu K, Inada Y, Qie YL, Takagi I, Ikeda M, Hashimoto O, Suzuka K, Eto S, Tanaka Y, Kaizu K. Inhibition of neuronal nitric oxide synthase ameliorates renal hyperfiltration in streptozotocin-induced diabetic rat. J Lab Clin Med 138: 177-185, 2001.
28. Jawerbaum A, Gonzalez ET, Carolina P, Debora S, Christian P, Gimeno MA. Diminished levels of prostaglandin E in type I diabetic oocyte-cumulus complexes. Influence of nitric oxide and superoxide dismutase. Reprod Fertil Dev 11: 105-110, 1999.
29. Jung K, Klotzek S, Schulze BD. Refinements of assays for low concentrations of inulin in serum. Nephron 54: 360-361, 1990.
30. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T. Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34: 146-154, 1999.
31. Khamaisi M, Keynan S, Bursztyn M, Dahan R, Reinhartz E, Ovadia H, Raz I. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol 102: p72-p80, 2006.
32. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 284: F1121-F1137, 2003.
33. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107: 889-898, 2001.
34. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: implication for renal function. Am J Physiol Renal Physiol 272: F460-F468, 1997.
35. Levine DZ, Iacovitti M, Robertson SJ. Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. II. Effects of renal mass reduction. Am J Physiol Regul Integr Comp Physiol 294: R1840-R1846, 2008.
36. Ling JJ, Sun YJ, Zhu DY, Chen Q, Han X. Potential role of NO in modulation of COX-2 expression and PGE2 production in pancreatic beta-cells. Acta Biochim Biophys Sin (Shanghai) 37: 139-146, 2005.
37. Lockhart CJ, Agnew CE, McCann A, Hamilton PK, Quinn CE, McCall DO, Plumb RD, McClenaghan V, McGivern CR, Harbinson MT, McVeigh G. Impaired flow mediated dilatation response in uncomplicated type 1 diabetes mellitus: influence of shear stress and microvascular reactivity. Clin Sci (Lond) 121: 129-139, 2011.
38. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52: 691-697, 2009.
39. Mathy-Hartert M, Deby-Dupont GP, Reginster JY, Ayache N, Pujol JP, Henrotin YE. Regulation by reactive oxygen species of interleukin1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis Cartilage 10: 547-555, 2002.
40. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf) 188: 123-127, 2006.
41. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10: 1778-1785, 1999.
42. Montanari A, Biggi A, Cabassi A, Pelloni I, Pigazzani F, Pinelli S, Pela GM, Musiari L, Cherney DZ. Renal hemodynamic response to L-arginine in uncomplicated, Type 1 diabetes mellitus: the role of buffering anions and tubuloglomerular feedback. Am J Physiol Renal Physiol (June 27, 2012). doi:10.1152/ajprenal.00149.2012.
43. Morath R, Klein T, Seyberth HW, Nusing RM. Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 10: 1851-1860, 1999.
44. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, Li Q. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 7: 36-44, 2011.
45. O'Byrne S, Forte P, Roberts LJ, 2nd Morrow JD, Johnston A, Anggard E, Leslie RD, Benjamin N. Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes 49: 857-862, 2000.
46. Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE. Reduction in basal nitric oxide activity causes albuminuria. Diabetes 60: 572-576, 2011.
47. Pecis M, Azevedo MJ, Gross JL. Glomerular hyperfiltration is associated with blood pressure abnormalities in normotensive normoalbuminuric IDDM patients. Diabetes Care 20: 1329-1333, 1997.
48. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 31: 1047-1060, 1998.
49. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10: 2382-2391, 1999.
50. Pyke KE, Tschakovsky Peak vs ME. total reactive hyperemia: which determines the magnitude of flow-mediated dilation? J Appl Physiol 102: 1510-1519, 2007.
51. Raij L. Nitric oxide in the pathogenesis of cardiac disease. J Clin Hypertens (Greenwich) 8: 30-39, 2006.
52. Schaefer WR, Seufert RJ, Casper FW, Zahradnik HP. Urinary excretion of 2,3-dinor-6-keto-PGF1 alpha and 11-dehydro-TXB2 by the gravid spontaneously hypertensive rat. Prostaglandins 52: 1-11, 1996.
53. Schneider MP, Klingbeil AU, Delles C, Schmidt BM, John S, Schmieder RE. Vitamin C augments the renal response to L-arginine in smokers. Nephrol Dial Transplant 18: 1512-1517, 2003.
54. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17: 1703-1709, 2006.
55. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41: 1426-1434, 1998.
56. Takenaka T, Mitchell KD, Navar LG. Contribution of angiotensin II to renal hemodynamic and excretory responses to nitric oxide synthesis inhibition in the rat. J Am Soc Nephrol 4: 1046-1053, 1993.
57. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302: R75-R83, 2012.
58. Tsikas D, Engeli S, Tank J, Stichtenoth DO, Jordan J. Comment on: Ott et al. Reduction in basal nitric oxide activity causes albuminuria Diabetes 2011;60:572-576. Diabetes 60: e21; author reply e22, 2011.
59. Villar IC, Francis S, Webb A, Hobbs AJ, Ahluwalia A. Novel aspects of endothelium-dependent regulation of vascular tone. Kidney Int 70: 840-853, 2006.
60. Wesson DE. Moving closer to an understanding of the hyperfiltration of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 290: R973-R974, 2006.
61. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke 29: 467-472, 1998.
62. Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HH. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci USA 89: 11993-11997, 1992.